In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Raises Doubts About India’s Wyeth Pneumonia Vaccinations

This article was originally published in PharmAsia News

Executive Summary

The pneumococcal conjugate vaccine India decided recently to add to its national immunization program apparently has no effect on the disease, according to the World Health Organization. A WHO bulletin said the PCV not only does not fight pneumonia, it actually increases asthma risks in children. A high-level committee of experts in India's Health Ministry earlier recommended including PCV in the immunization program and the ministry said it would do so within a year despite its high cost of more than $90 per child. The WHO bulletin advised governments to assess the cost of the Wyeth drug given its questionable effect, but Wyeth said the bulletin item contained inaccuracies and misleading statements. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel